← All trials
NCT05888870
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2023
- Primary completion
- Dec 1, 2026
- Completion date
- Dec 1, 2026
- First posted
- Jun 5, 2023
- Last posted
- Jun 22, 2023
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- Sinocelltech Ltd.Collaborator
- China Academy of Chinese Medical SciencesOverall official - principal investigator
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.